ORICULA THERAPEUTICS
Oricula Therapeutics develops and commercializes drugs to prevent hearing loss. The company was incorporated in 2013 and is based in Seattle, Washington.
ORICULA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2013-01-01
Address:
Wa Keeney, Kansas, United States
Country:
United States
Website Url:
http://www.oricularx.com
Total Employee:
1+
Status:
Active
Contact:
2063227526
Total Funding:
2.05 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Content Delivery Network Euro AJAX Libraries API Typekit Squarespace Squarespace Add To Cart
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Current Employees Featured
Graham Johnson Co-Founder & CSO @ Oricula Therapeutics
Co-Founder & CSO
2013-01-01
Vince Groppi Co Founder and Member of the Board of Directors @ Oricula Therapeutics
Co Founder and Member of the Board of Directors
2013-11-01
Malcolm A. Gleser CEO @ Oricula Therapeutics
CEO
Founder
Investors List
University of Washington
University of Washington investment in Funding Round - Oricula Therapeutics
Official Site Inspections
http://www.oricularx.com
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Oricula Therapeutics"
Oricula Therapeutics - Crunchbase Company Profile & Funding
Oricula Therapeutics develops and commercializes drugs to prevent hearing loss. The company was incorporated in 2013 and is based in Seattle, Washington.See details»
Oricula Therapeutics
Medicines to Preserve Hearing Developing Products. Oricula Therapeutics' first oral product (ORC-13661), a medicine to preserve hearing during aminoglycoside therapy, has successfully completed Phase 1 human testing for safety, …See details»
About Oricula — Oricula Therapeutics
Oricula Therapeutics, LLC, is a start-up biotechnology company with a mission to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging. Our …See details»
Background - Oricula Therapeutics
Oricula Therapeutics, LLC, is a start-up biotechnology company with a mission to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging. Our …See details»
Oricula Therapeutics LLC - govtribe.com
Oricularx.com Primary NAICS Category 325412 - Pharmaceutical Preparation Manufacturing SBA Certifications Self-Certifications More + Entity Structure Partnership or Limited Liability …See details»
Oricula Therapeutics LLC Overview | SignalHire Company Profile
Phone Number: 206-322-7526: Headquarters Location: Seattle, Washington, US Seattle, Washington, US SIC Code: 2834, 2836: DMA Code: Seattle Metropolitan AreaSee details»
Oricula Therapeutics Company Profile | Management and
John@oricularx.com: Oricula Therapeutics Top Competitors. Company Employees Revenue Top technologies; TD2 ) Inc. 17: $3.9 M: Cellectar Biosciences Inc. 15: $3.8 M: ArQule Inc. 34: …See details»
Oricula Therapeutics - Overview, News & Similar companies
Sep 27, 2018 Who is Oricula Therapeutics. Founded in 2013, privately held Oricula Therapeutics, LLC, headquartered in Seattle, Wash., is one of the first biotech companies …See details»
Oricula Therapeutics Company Profile 2024: Valuation, …
Oricula Therapeutics General Information Description. Operator of a biotechnology company intended to offer medication to prevent hearing loss in patients. The company's services mainly focus on protecting inner ear hair …See details»
Oricula Therapeutics LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oricula Therapeutics LLC of Kalamazoo, MI. Get the latest business insights from Dun & Bradstreet.See details»
Oricula Therapeutics Company Profile -Sales, Contacts, …
Oricula Therapeutics is in the Pharmaceutical Preparations industry within the Chemicals and Allied Products sector and has been in business for approximately 11 years.See details»
Oricula’s Competitors, Revenue, Number of Employees, Funding
Oricula’s Profile, Revenue and Employees. Oricula is a biotechnology company that develops and commercializes drugs to prevent hearing loss. Oricula’s primary competitors include …See details»
Oricula Therapeutics LLC - Company Profile & Staff Directory
Oricula Therapeutics LLC is a company based out of 474 39th Avenue East, Seattle, Washington, United States.See details»
Oricula Therapeutics - VentureRadar
"Oricula Therapeutics is a start-up biotechnology company with a mission to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging.See details»
Vince Groppi - Chief Executive Officer - Oricula ... - LinkedIn
Chief Executive Officer at Oricula Therapeutics LLC · I co-founded Oricula Therapeutics which is a biotechnology company with a phase 2 drug for treating drug-induced hearing loss. I am also …See details»
Our Team - Oricula Therapeutics
Vince Groppi, PhD ORICULA THERaPEUTICS CEO Molecular Pharmacologist. Dr. Groppi is the Director, Center for Discovery of New Medicines and Director, Center for Chemical Genomics …See details»
Oricula Therapeutics LLC (Oricula Therapeutics LLC) - 药物管线_专 …
INTRODUCTION Aminoglycoside (AG) antibiotics, such as tobramycin, are known to be ototoxic but important clinically due to their bactericidal efficacy. Persons with cystic fibrosis (CF) are at …See details»
Contact — Oricula Therapeutics
Contact us. Vincent Groppi, CEO groppi@oricularx.com. Tel: +1 (269) 760-1159See details»
Malcolm A. Gleser - Oricula Therapeutics LLC, Seattle - AllPeople
Malcolm.gleser@oricularx.com. Search Background Check Edit Listing. ... They may have been associated with this organization before or after these years as well. Oricula Therapeutics LLC …See details»
Research - Oricula Therapeutics
Developing a SAR. Oricula's ORC-13661 was developed through an iterative chemistry approach using ORC-0001 as the starting structure. The new compound was over 25x more potent, with …See details»